To End AIDS in the United States, Stay True to the National HIV/AIDS Strategy

By Judith Auerbach, Robert Bank, Chris Collins, JD Davids, Rebecca Haag, David Ernesto Munar, Dana van Gorder, Phill Wilson and A. Toni Young Ten years ago, hundreds of organizations and individuals signed a petition calling on all presidential candidates to create a national AIDS strategy. We…Read More

CROI 2017: The best HIV cure will be built with us, not just for us

Among the world’s top scientific conferences on HIV, the Conference on Retroviruses and Opportunistic Infections (CROI) stands among the most prestigious. Only a handful of the top submissions of new scientific data are deemed worthy of stage time. Submissions deemed less worthy are relegated to the…Read More

CROI 2017: What’s Up with PrEP and STIs?

Critics have been warning since the concept of oral PrEP was in its infancy that it would lead to major increases in condomless sex among users and a corresponding dramatic spike in sexually transmitted infections (STIs). So far, the data have been inconclusive. A journal article…Read More

CROI 2017: Dapivirine ring for PrEP does not lower effectiveness of hormonal contraception

In previous study, certain HIV medications were found to lower the effectiveness of some hormonal contraceptives, including the NNRTI efavirenz (Sustiva). This presented concerns about the experimental NNRTI dapivirine that was already being used as a vaginal ring for PrEP in clinical study. A presentation at…Read More

CROI 2017: Two-drug maintenance regimen controls HIV as well as standard treatment

In a late-breaker presentation at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, data from the SWORD 1 & 2 studies showed that a two-drug regimen of dolutegravir (Tivicay, DTG) + rilpivirine (Edurant, RPV) suppressed HIV as well as various regimens of three…Read More

CROI 2017: New two-drug maintenance regimen continues to suppress HIV over 144 weeks

At the 2017 Conference on Retroviruses and Opportunistic Infections (CROI), results from the LATTE study showed that the 2-drug regimen of the integrase inhibitor cabotegravir (CAB) + the NNRTI rilpirivine (RPV, Edurant) suppressed HIV levels as well as a 3-drug efavirenz (Sustiva) regimen through 144 weeks….Read More

CROI 2017: New integrase inhibitor bictegravir suppresses HIV as well as dolutegravir in first line therapy

At the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, 48-week results from a somewhat small Phase 2 study in people new to treatment showed that the Gilead Science’s experimental integrase inhibitor bictegravir suppressed HIV levels as well as ViiV’s integrase inhibitor dolutegravir (Tivicay)….Read More